BeiGene Inks Over $2 Billion Deal as China's First PD-1/VEGF-A/CTLA-4 Trispecific Antibody HH160 Enters Clinical Trials

Jul 03, 2026 13:52 CST Updated 13:52

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Huahui Health

Innovative Drug Developer

CStone Pharmaceuticals

Innovative Oncology Immunotherapy and Precision Medicine Drug Developer

Recently, the official website of the Drug Clinical Trial Registration and Information Publicity Platform showed that,Huahui Health registered aEvaluation in Patients with Advanced or Metastatic Solid TumorsHH160 Monotherapyor in combination with other antineoplastic agentsAn open-label, multicenter, Phase I clinical trial evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity.

Source:Official Website of the Drug Clinical Trial Registration and Information Publicity Platform

HH160 is a targetedPD-1, CTLA-4, and VEGF-Atrispecific antibody. In April 2026, BeOne andHuahui Health has entered into a global exclusive option, license, and collaboration agreement for this product, with a total value of up to$2.024 billion, with an upfront payment of $20 million and an exercise payment of $100 million.

The launch ofHH160 First Clinical Study,Currently, only monotherapy studies are being conducted in China.. The study plans to enroll 45 subjects in China and 477 subjects internationally. The primary endpoint isAdverse Events Occurring During Treatment（TEAE）, Serious Adverse Events（SAE）and dose-limiting toxicities as defined in the protocol（DLT）Incidence of events, andMaximum Tolerated Dose of HH160（MTD）or maximum administered dose（MAD）。

Secondary endpoints include based onInvestigator-assessed objective response rate, disease control rate, duration of response, progression-free survival, and time to response; pharmacokinetic parameters of HH160.

Insight database shows that there are currently two PD-1/VEGF-A/CTLA-4 trispecific antibodies under development globally. The other one isCStone Pharmaceuticals' CS2009, currently conducting Phase I/II clinical trials.

Editor: Yueya

Cover source:ZCOOL Hello

Disclaimer:This article is for informational purposes only, does not represent the position or views of Insight, and does not constitute a recommendation or introduction to treatment plans. If needed, please consult and contact legitimate medical institutions.